Glaucoma, Closed-Angle, Glaucoma, Narrow-Angle, Glaucoma, Angle-Closure
Conditions
Keywords
Laser peripheral iridotomy, topical anti-inflammatory drops
Brief summary
The purpose of this study is to evaluate the efficacy and need for prescribing anti-inflammatory topical drops to patients undergoing laser peripheral iridotomy.
Detailed description
Primary closed angle glaucoma is responsible to almost half glaucoma related blindness around the world. Laser peripheral iridotomy (LPI) is a common and simple treatment used for both treatment and prevention of acute angle closure event. Anti-inflammatory drops are commonly prescribed to patients undergoing LPI in order to prevent or reduce post-treatment discomfort. However, to date, there are no specific guidelines for post LPI anti-inflammatory treatment, nor sufficient clinical evidence regarding the efficacy of such treatment. In the current study, the investigators aim to evaluate the effect of topical steroids and non-steroidal anti-inflammatory drugs (NSAIDs) on post LPI symptoms and inflammation markers.
Interventions
DRUGDexamethasone Disodium Phosphate 0.1%
four drops a day for four days after LPI treatment
DRUGNepafenac 0.1%
four drops a day for four days after LPI treatment
DRUGHydroxyethylcellulose 0.19%
four drops a day for four days after LPI treatment
Sponsors
Sheba Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of primary narrow/closed angle by gonioscopy * Able to give consent * Ability to attend follow-up visits
Exclusion criteria
* Corneal disease preventing sufficient evaluation of the angle * Secondary closed angle (e.g. uveitis related) * Pregnant women * Previous eye surgery other than laser refractive correction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | At four days post LPI treatment | Using VAS pain scale |
| Symptoms score | At four days post LPI treatment | Using a modified questionnaire based on the ocular surface disease index. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Grading of cells in the anterior chamber | At four days post LPI treatment | Assessed by counting the number of cells in the anterior chamber and applying the SUN working group grading scheme for anterior chamber cells |
| Patency of LPI by visualisation | up to 30 days post LPI treatment | Assessed on slit-lamp examination using transilumination and visualising the site of LPI treatment for the presence (patent) or obsence (closed) of transilumination defect |
| Grading of flare in anterior chamber | At four days post LPI treatment | Assessed by counting the number of cells in the anterior chamber and applying the SUN working group grading scheme for anterior chamber flare |
Countries
Israel
Contacts
Primary ContactAri Leshno, MD
Outcome results
None listed